Literature DB >> 25100280

Type of MRI contrast, tissue gadolinium, and fibrosis.

Catherine Do1, Jeffrey L Barnes2, Chunyan Tan1, Brent Wagner3.   

Abstract

It has been presupposed that the thermodynamic stability constant (K(therm)) of gadolinium-based MRI chelates relate to the risk of precipitating nephrogenic systemic fibrosis. The present study compared low-K(therm) gadodiamide with high-K(therm) gadoteridol in cultured fibroblasts and rats with uninephrectomies. Gadolinium content was assessed using scanning electron microscopy equipped with energy-dispersive X-ray spectroscopy in paraffin-embedded tissues. In vitro, fibroblasts demonstrated dose-dependent fibronectin generation, transforming growth factor-β production, and expression of activated myofibroblast stress fiber protein α-smooth muscle actin. There were negligible differences with respect to toxicity or proliferation between the two contrast agents. In the rodent model, gadodiamide treatment led to greater skin fibrosis and dermal cellularity than gadoteridol. In the kidney, both contrast agents led to proximal tubule vacuolization and increased fibronectin accumulation. Despite large detectable gadolinium signals in the spleen, skin, muscle, and liver from the gadodiamide-treated group, contrast-induced fibrosis appeared to be limited to the skin and kidney. These findings support the hypothesis that low-K(therm) chelates have a greater propensity to elicit nephrogenic systemic fibrosis and demonstrate that certain tissues are resistant to these effects.

Entities:  

Keywords:  animals; fibrosis; gadolinium/adverse effects; magnetic resonance imaging/adverse effects; nephrogenic fibrosing dermopathy; skin diseases

Mesh:

Substances:

Year:  2014        PMID: 25100280      PMCID: PMC4250231          DOI: 10.1152/ajprenal.00379.2014

Source DB:  PubMed          Journal:  Am J Physiol Renal Physiol        ISSN: 1522-1466


  37 in total

Review 1.  Mechanisms of fibrogenesis.

Authors:  Tatiana Kisseleva; David A Brenner
Journal:  Exp Biol Med (Maywood)       Date:  2008-02

Review 2.  Clinical and biological consequences of transmetallation induced by contrast agents for magnetic resonance imaging: a review.

Authors:  Jean-Marc Idée; Marc Port; Isabelle Raynal; Michel Schaefer; Soizic Le Greneur; Claire Corot
Journal:  Fundam Clin Pharmacol       Date:  2006-12       Impact factor: 2.748

3.  Gadolinium is detectable within the tissue of patients with nephrogenic systemic fibrosis.

Authors:  Whitney A High; Reed A Ayers; John Chandler; Gary Zito; Shawn E Cowper
Journal:  J Am Acad Dermatol       Date:  2006-11-09       Impact factor: 11.527

4.  Risk for nephrogenic systemic fibrosis with gadoteridol (ProHance) in patients who are on long-term hemodialysis.

Authors:  Robert F Reilly
Journal:  Clin J Am Soc Nephrol       Date:  2008-02-20       Impact factor: 8.237

5.  A preclinical study to investigate the development of nephrogenic systemic fibrosis: a possible role for gadolinium-based contrast media.

Authors:  Martin A Sieber; Hubertus Pietsch; Jakob Walter; Wolfram Haider; Thomas Frenzel; Hanns-Joachim Weinmann
Journal:  Invest Radiol       Date:  2008-01       Impact factor: 6.016

6.  Mitogenic signaling via platelet-derived growth factor beta in metanephric mesenchymal cells.

Authors:  Brent Wagner; Jill M Ricono; Yves Gorin; Karen Block; Mazen Arar; Dan Riley; Goutam Ghosh Choudhury; Hanna E Abboud
Journal:  J Am Soc Nephrol       Date:  2007-10-17       Impact factor: 10.121

7.  Gadodiamide contrast agent 'activates' fibroblasts: a possible cause of nephrogenic systemic fibrosis.

Authors:  M Edward; J A Quinn; S Mukherjee; M-B V Jensen; A G Jardine; P B Mark; A D Burden
Journal:  J Pathol       Date:  2008-04       Impact factor: 7.996

Review 8.  Nephrogenic systemic fibrosis: early recognition and treatment.

Authors:  Eleanor A Knopp; Shawn E Cowper
Journal:  Semin Dial       Date:  2008-01-23       Impact factor: 3.455

Review 9.  Nephrogenic systemic fibrosis risk: is there a difference between gadolinium-based contrast agents?

Authors:  Jeffrey G Penfield; Robert F Reilly
Journal:  Semin Dial       Date:  2008-01-23       Impact factor: 3.455

Review 10.  The role of the fibrocyte, a bone marrow-derived mesenchymal progenitor, in reactive and reparative fibroses.

Authors:  Alberto Bellini; Sabrina Mattoli
Journal:  Lab Invest       Date:  2007-07-02       Impact factor: 5.662

View more
  20 in total

Review 1.  Gadolinium-based contrast agents: why nephrologists need to be concerned.

Authors:  Katarina Leyba; Brent Wagner
Journal:  Curr Opin Nephrol Hypertens       Date:  2019-03       Impact factor: 2.894

2.  Nephrogenic Systemic Fibrosis Is Mediated by Myeloid C-C Chemokine Receptor 2.

Authors:  Catherine Do; Viktor Drel; Chunyan Tan; Doug Lee; Brent Wagner
Journal:  J Invest Dermatol       Date:  2019-04-09       Impact factor: 8.551

3.  Balanced regulation of the CCN family of matricellular proteins: a novel approach to the prevention and treatment of fibrosis and cancer.

Authors:  Bruce L Riser; Jeffrey L Barnes; James Varani
Journal:  J Cell Commun Signal       Date:  2015-12-23       Impact factor: 5.782

4.  Impact of chelation timing on gadolinium deposition in rats after contrast administration.

Authors:  John P Prybylski; Carla Coste Sanchez; Michael Jay
Journal:  Magn Reson Imaging       Date:  2018-10-12       Impact factor: 2.546

5.  Gadolinium-based contrast agents: Stimulators of myeloid-induced renal fibrosis and major metabolic disruptors.

Authors:  Catherine Do; Bridget Ford; Doug Yoon Lee; Chunyan Tan; Patricia Escobar; Brent Wagner
Journal:  Toxicol Appl Pharmacol       Date:  2019-05-10       Impact factor: 4.219

Review 6.  Pathophysiology of gadolinium-associated systemic fibrosis.

Authors:  Brent Wagner; Viktor Drel; Yves Gorin
Journal:  Am J Physiol Renal Physiol       Date:  2016-05-04

7.  Albumin-based nanoparticles as contrast medium for MRI: vascular imaging, tissue and cell interactions, and pharmacokinetics of second-generation nanoparticles.

Authors:  E A Wallnöfer; G C Thurner; C Kremser; H Talasz; M M Stollenwerk; A Helbok; N Klammsteiner; K Albrecht-Schgoer; H Dietrich; W Jaschke; P Debbage
Journal:  Histochem Cell Biol       Date:  2020-10-11       Impact factor: 4.304

8.  Centrality of bone marrow in the severity of gadolinium-based contrast-induced systemic fibrosis.

Authors:  Viktor R Drel; Chunyan Tan; Jeffrey L Barnes; Yves Gorin; Doug-Yoon Lee; Brent Wagner
Journal:  FASEB J       Date:  2016-05-24       Impact factor: 5.191

Review 9.  Gadolinium Retention: A Research Roadmap from the 2018 NIH/ACR/RSNA Workshop on Gadolinium Chelates.

Authors:  Robert J McDonald; Deborah Levine; Jeffrey Weinreb; Emanuel Kanal; Matthew S Davenport; James H Ellis; Paula M Jacobs; Robert E Lenkinski; Kenneth R Maravilla; Martin R Prince; Howard A Rowley; Michael F Tweedle; Herbert Y Kressel
Journal:  Radiology       Date:  2018-09-11       Impact factor: 11.105

10.  Overlapping roles of NADPH oxidase 4 for diabetic and gadolinium-based contrast agent-induced systemic fibrosis.

Authors:  Francesca Bruno; Joshua DeAguero; Catherine Do; Doug Yoon Lee; Chunyan Tan; G Patricia Escobar; Brent Wagner
Journal:  Am J Physiol Renal Physiol       Date:  2021-02-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.